Health Canada Authorizes Moderna Covid-19 Vaccine Targeting The Omicron XBB.1.5; Authorized Use Of Moderna Spikevax™ Covid-19 Vaccine Targeting Omicron Xbb.1.5 Subvariant For People Six Months Of Age And Older
Portfolio Pulse from Benzinga Newsdesk
Health Canada has authorized the use of Moderna's Spikevax Covid-19 vaccine targeting the Omicron XBB.1.5 subvariant for people aged six months and older.
September 12, 2023 | 3:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's Spikevax Covid-19 vaccine has been authorized by Health Canada for use against the Omicron XBB.1.5 subvariant in people aged six months and older.
The authorization of Moderna's Spikevax Covid-19 vaccine by Health Canada for use against the Omicron XBB.1.5 subvariant could potentially increase the demand for the vaccine, leading to increased revenues for Moderna. This could have a positive impact on Moderna's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100